Compare Omnicom Group Inc. (OMC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs TransMedics Group Inc — how do they compare? Omnicom Group Inc. trades at $76.69 (market cap $20.97B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: Omnicom Group Inc. is far larger — about 7.7× TransMedics Group Inc's market cap, and Omnicom Group Inc. pays a 4.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and TransMedics Group Inc for 24 Days on average.
| OMC | TMDX | |
|---|---|---|
Market Cap | $20.97B | $2.74B |
Volume | 2,092,899 | 949,331 |
Sector | Media | Health |
52-Week High | $88.94 | $150.42 |
52-Week Low | $67.27 | $61.99 |
Typical Hold Time | 63 Days | 24 Days |
Enterprise Value | $29.05B | $3.13B |
Dividend Yield | 4.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $76.32, up 1.94% on the day, with a bullish technical signal but mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, with a high P/E ratio of 206.62 but attractive P/S of 0.86. Recent news highlights leadership in digital marketing and $3.3 billion in new H1 2026 billings, supporting positive sentiment.
Outlook is cautiously optimistic given analyst consensus price target of $100.50 (32% upside) and strong institutional interest, but risks include ad market volatility, high debt, and thin net margins. The stock offers value through a 4.2% dividend yield and post-merger synergies, though investors should monitor earnings consistency and macroeconomic pressures on advertising spend.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
